# Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

> **NCT04510311** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 3-[18F]Fluoro-para-hydroxyphenethylguanidine
- **DRUG:** [123I] metaiodobenzylguanidine
- **DIAGNOSTIC_TEST:** Positron emission tomography/computed tomography scan
- **DIAGNOSTIC_TEST:** Planar scintigraphy scan
- **DIAGNOSTIC_TEST:** Single photon emission computed tomography/computed tomography scan

## Key facts

- **NCT ID:** NCT04510311
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510311, "Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04510311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*